New heart MRI study could simplify diagnosis without dye
NCT ID NCT07354646
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will use cardiac MRI scans to measure heart tissue in 2000 people with various heart conditions, such as heart attacks, cardiomyopathies, and myocarditis. The goal is to create a reference map of normal and abnormal tissue values, which may help doctors diagnose diseases more easily. Researchers also want to see if a simpler scan without contrast dye can replace the more complex one.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors diagnose heart diseases more accurately using simpler MRI scans, potentially reducing the need for contrast dye.
- What could go wrong
- This is an observational study, not a treatment trial, so it won't directly improve patient outcomes. Results may not apply to all populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 2,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2020
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population comprises a diverse cohort of patients with a comprehensive spectrum of myocardial conditions, including Fabry disease, iron overload, atrial fibrillation, hypertension, aortic stenosis, chronic and acute myocardial infarction, hypertrophic, dilated, restrictive, and arrhythmogenic cardiomyopathies, acute and chronic myocarditis, cardiac amyloidosis, cardiac tumors, congenital heart disease, and cases of suspected transplant rejection. This population represents a wide array of pathophysiological processes affecting the myocardium, ensuring broad clinical relevance and generalizability of the study findings.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adult patients (≥18 years) with clinically diagnosed myocardial diseases based on current international guidelines. 2. Specific disease categories include: * Cardiomyopathies (HCM, DCM, RCM, ACM) * Infiltrative disorders (cardiac amyloidosis, Fabry disease) * Inflammatory conditions (acute/chronic myocarditis) * Ischemic heart disease (acute/chronic MI) * Valvular heart disease (aortic stenosis) * Arrhythmic conditions (atrial fibrillation) * Metabolic disorders (iron-overload) * Neoplastic conditions (cardiac tumors) * Congenital heart disease * Post-transplant evaluation 3. All diagnoses must be confirmed using established guideline-based criteria: * Echocardiographic parameters meeting disease-specific cutoffs * Cardiac MRI findings consistent with current consensus criteria * Laboratory biomarkers supporting respective diagnoses * Histopathological confirmation when clinically indicated Exclusion Criteria: * Presence of multiple cardiomyopathy diseases or risk factors simultaneously * Contraindications to CMR examination * Poor image quality precluding accurate T1 mapping analysis * Incomplete clinical data for definitive diagnosis confirmation * Pregnancy or lactation * Inability to provide informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Arrhythmogenic cardiomyopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Every minute counts: study tracks how delays shape heart attack survival
- The heart rhythm threat hiding in heart attack wards
- 3,000 hearts, one goal: mapping how hypertrophic cardiomyopathy unfolds in china
- Heart pump timing put to the test in deadly heart attack shock
- Cancer immunotherapy can attack the heart: massive data hunt seeks who is most vulnerable
- AI on your phone: the future of heart attack detection in the field?